
|Articles|October 18, 2013
- B-Cell Malignancies
- Volume 1
- Issue 1
The Utility of Pomalidomide in R/R Multiple Myeloma
Author(s)Manish Sharma, MD
Manish Sharma, MD, from the Kimmel Cancer Center at Jefferson, comments on the use of pomalidomide in relapsed/refractory multiple myeloma.
Manish Sharma, MD, from the Kimmel Cancer Center at Jefferson, comments on the use of pomalidomide in relapsed/refractory multiple myeloma.
In an updated analysis of the phase III MM-003 trial, Celgene International Sarl reported on a new progression-free survival analysis and final overall survival.
Articles in this issue
about 12 years ago
Updated Data for Pomalidomide in Relapsed/Refractory Multiple Myelomaabout 12 years ago
Clinical Advances in Mantle Cell Lymphomaabout 12 years ago
Emerging Therapies for the Treatment of Mantle Cell Lymphomaabout 12 years ago
In Brief: Phase III Trials in Multiple Myelomaabout 12 years ago
Therapy for CLL: Where Are We Today? Where Will We Be Tomorrow?about 12 years ago
BTK and PI3K Inhibitors in Development for Chronic Lymphocytic Leukemiaabout 12 years ago
Transforming Expectations and Outcomes With Targeted Therapiesabout 12 years ago
Dr. Zelenetz Discusses Diagnosis and Treatment Issues in Indolent NHL




































